ULIMORELIN

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C30H39FN4O4
Molecular Weight	538.6535
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H]1CN[C@@H](C2CC2)C(=O)N(C)[C@H](C)C(=O)N[C@H](CC3=CC=C(F)C=C3)C(=O)NCCCC4=CC=CC=C4O1

InChI

InChIKey=WGYPAJVJMXQXTR-ABNZCKJZSA-N

InChI=1S/C30H39FN4O4/c1-19-18-33-27(23-12-13-23)30(38)35(3)20(2)28(36)34-25(17-21-10-14-24(31)15-11-21)29(37)32-16-6-8-22-7-4-5-9-26(22)39-19/h4-5,7,9-11,14-15,19-20,23,25,27,33H,6,8,12-13,16-18H2,1-3H3,(H,32,37)(H,34,36)/t19-,20-,25-,27+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C30H39FN4O4
Molecular Weight	538.6535
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://adisinsight.springer.com/drugs/800021027 | https://www.ncbi.nlm.nih.gov/pubmed/22106937 | https://www.ncbi.nlm.nih.gov/pubmed/25687251

Ulimorelin (TZP101) is a small molecule, intravenously administered, ghrelin receptor agonist that is being developed by Lyric Pharmaceuticals. Ulimorelin stimulates intestinal motility, but also reduces blood pressure in rodents and humans and dilates blood vessels. It has been proposed as a treatment for intestinal motility disorders. Ulimorelin has progressed to phase III human clinical trials for the treatment of postoperative ileus.

Originator

Approval Year

PubMed

Title	Date	PubMed
Analysis of the ghrelin receptor-independent vascular actions of ulimorelin.	2015-04-05	25687251
The mechanism of enhanced defecation caused by the ghrelin receptor agonist, ulimorelin.	2014-02	24304447
Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic.	2011-12-22	22106937

Patents

Sample Use Guides

In Vivo Use Guide

Partial bowel resection: Thirty-minute intravenous infusions (160 ug/kg, 480 ug/kg ulimorelin, or placebo) once daily were started within 60 minutes after the end of surgery and ended at the first of the following: primary efficacy end point fulfilled (defined below), hospital discharge, or 7 days treatment.

Route of Administration: Intravenous

In Vitro Use Guide

Ulimorelin (0.03-30uM) inhibited phenylephrine-induced contractions of rat saphenous (IC50=0.6uM; Imax=66±5%; n=3-6) and mesenteric arteries (IC50=5uM, Imax=113±16%; n=3-4). In mesenteric arteries, ulimorelin, 1-10uM, caused a surmountable rightward shift in the response to phenylephrine (0.01-1000uM; pA2=5.7; n=3-4). Ulimorelin is an agonist of G-protein coupled receptor (Ki=16 nM, EC50=29 nM).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:52:42 GMT 2025` Edited by `admin` on `Mon Mar 31 18:52:42 GMT 2025`
Record UNII	LGI67MCW2S
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ULIMORELIN

Official Name

English

ULIMORELIN [MI]

Preferred Name

English

(2R,5S,8R,11R)-5-CYCLOPROPYL-11-((4-FLUOROPHENYL)METHYL)-2,7,8-TRIMETHYL- 2,3,4,5,7,8,10,11,13,14,15,16-DODECAHYDRO-6H-1,4,7,10,13- BENZOXATETRAAZACYCLOOCTADECINE-6,9,12-TRIONE

Systematic Name

English

Ulimorelin [WHO-DD]

Common Name

English

ulimorelin [INN]

Common Name

English

TZP-101 FREE BASE

Code

English

ULIMORELIN [USAN]

Common Name

English

2H-1,4,7,10,13-BENZOXATETRAAZACYCLOOCTADECINE-6,9,12(3H)-TRIONE, 5-CYCLOPROPYL-11- ((4-FLUOROPHENYL)METHYL)-4,5,7,8,10,11,13,14,15,16-DECAHYDRO-2,7,8-TRIMETHYL-, (2R,5S,8R,11R)-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C84868